Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MRK

3 Healthcare Stocks Under $100 to Buy Right Now

The rising prevalence of chronic diseases and the aging population are major growth drivers for the healthcare industry. In addition, increased investments in technological advancements should further bolster the industry’s growth. Thus, we think it may be prudent to buy quality healthcare stocks Pfizer Inc. (PFE), Merck & Co. (MRK),…

StockNews.com

3 Stocks Bullish Traders Tend to Fall in Love With

The Fed’s continued monetary policy tightening and consequent recession fears are expected to keep the stock market under pressure in the upcoming months. However, bullish traders could keep paying with fundamentally strong stocks The Coca-Cola Company (KO), AbbVie (ABBV), and Merck & Co. (MRK). Read more….

StockNews.com

2 Reliable Drug Stocks to Buy and Hold for Big-Time Gains

Persistent rate hikes by the Fed and rising odds of a recession have aggravated market turbulence and led investors to seek refuge in defensive sectors such as healthcare. Defensive stocks tend to perform well in declining markets due to the steady demand for their products. Hence, consistent dividend-yielding drug stocks…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

What Are Whales Doing With Merck & Co

Someone with a lot of money to spend has taken a bullish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

This Is What Whales Are Betting On Merck & Co

A whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 17 strange trades.

Benzinga

5 Dividend Stocks to Buy and Hold Forever

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…

StockNews.com

Dogs of the Dow: 2 Stocks to Buy and 2 to Hold

The stock market has rebounded lately from the decline in the year's first half, thanks to better-than-expected corporate earnings and the expectation of easing inflationary pressure. However, a still uncomfortable inflation level and the possible aggressive rate hikes could keep the market volatile. The Dogs of the Dow investment strategy…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Merck & Co Whale Trades For August 11

A whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 10 strange trades.

Benzinga

4 "Strong Buy" Stocks for a Fear-Driven Market

Even though the inflation declined slightly from the 40-year high in July, it stayed elevated. Therefore, the Fed could maintain its hawkish stance on tightening monetary policy, which will drive market volatility. Amid this fear-driven market, we think it could be prudent to invest in fundamentally sound stocks AbbVie (ABBV),…

StockNews.com

2 Pharmaceutical Stocks That Could Outperform the Market in the Long Term

The pharmaceutical industry is growing rapidly with advancements in drug manufacturing and a paradigm shift to personalized medicines. Moreover, despite soaring prices, supportive fiscal policies are expected to keep consumer demand stable. Quality pharmaceutical stocks Pfizer (PFE) and Merck (MRK) have outperformed the broader market over the past year and…

StockNews.com

3 Large-Cap Healthcare Stocks to Buy for Bigger Gains

Due to the inelastic demand and rising investments, the healthcare sector is witnessing investor confidence amid these uncertain market conditions. Although persistent macroeconomic headwinds might affect stocks in this space, investors could consider buying dividend-paying large-cap stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and UnitedHealth Group (UNH) to…

StockNews.com

2 Stocks Hedge Funds Have Been Buying up in 2022

Amid the bear market, hedge funds have been buying shares of Merck & Co. (MRK) and Pfizer (PFE). This, along with the strong fundamentals and growth prospects of these stocks, makes them good additions to your watchlist. Let’s discuss.

StockNews.com

Pfizer (PFE), BioNTech Seek EU Nod For Omicron-Based COVID Jab

Pfizer (NYSE: PFE) and its partner, BioNTech (NASDAQ: BNTX) announced that they have completed the submission of a regulatory application to the European Medicines Agency (EMA), which seeks authorization for thei

Benzinga

5 Highest Dividend-Paying Stocks in the Dow

The stock market has been under immense pressure owing to the growing concerns over a potential recession due to the tightening of monetary policy. Hence, we think it could be worth adding the Dow’s highest dividend-paying stocks, Goldman Sachs (GS), Merck (MRK), Coca-Cola Company (KO), Home Depot (HD), and McDonald's…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Analysts Just Issued Upgrades on These 4 Buy-Rated Stocks

The blistering inflation and rising recession odds have led to low consumer sentiment. And the market volatility is expected to remain in the near term. So, we think fundamentally solid stocks Lamar Advertising (LAMR), EPR Properties (EPR), Merck & Co. (MRK), and Tenaris (TS), which analysts recently upgraded, could be…

Benzinga

Looking At Merck & Co's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 15 strange trades.

StockNews.com

4 Pharmaceutical Stocks with Tremendous Growth Potential

The global pharmaceutical industry has witnessed robust growth over the past few years. The rapidly aging population and continued breakthroughs in drug development are expected to keep driving the industry’s growth. Thus, we think pharmaceutical stocks Assertio Holdings (ASRT), Bayer (BAYRY), Eagle Pharmaceuticals (EGRX), and Merck (MRK), which possess solid…

Benzinga

What Are Whales Doing With Merck & Co

A whale with a lot of money to spend has taken a noticeably bullish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 11 strange trades.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Merck Discussing Another Drugmaker Buyout -- Buy Or Sell?

Merck & Co., Inc. (MRK) reported solid first-quarter results beating analysts’ estimates for sales and earnings. In addition, given that the company is in talks to acquire another biotech firm to boost its cancer-drug portfolio, would it be wise to buy the stock now? Let’s discuss.

Benzinga

Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ

Merck & Co Inc (NYSE:MRK) is pushing forward with a potential deal for Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported, citing people familiar with the matter. The Journal mentioned that the deal could be one of the largest takeovers of the year. The Wall Street Journal reported last week that Merck was in talks to…

Benzinga

Merck & Co Whale Trades For June 23

Someone with a lot of money to spend has taken a bearish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know

SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN).

Benzinga

Merck To Start Pivotal Trial For Next-Gen Pneumococcal Vaccine Next Month

Merck & Co Inc (NYSE:MRK) presented results from the Phase 1/2 study, evaluating V116 in pneumococcal vaccine-naïve adults 18-49 years of age (Phase 1) and 50 years of age and older (Phase 2). Data were shared at the International Symposium on Pneumococci and Pneumococcal Diseases. V116 targets serotypes that account for 85% of…

StockNews.com

3 Drug Manufacturers to Buy on the Pullback

The global pharmaceutical industry is expected to thrive with the lingering impact of COVID-19 and the evolving healthcare landscape. Given the industry’s solid prospects, the pullbacks in drug manufacturing stocks Merck & Co (MRK), Bristol-Myers Squibb (BMY), and Bayer Aktiengesellschaft (BAYRY) amid the broader market correction preset solid buying opportunity.…

Benzinga

Merck Shows Takeover Interest In Seagen: WSJ

Merck & Co Inc (NYSE:MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagen's market value of roughly $28 billion. According to the report, some people said other unnamed suitors are also eying Seagen, a…

1 … 6 7 8 9

People

Dipanjan BanchurSince

722 stories

Santanu RoyHaving

215 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.